Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer | Journal of Translational Medicine BioMed Central Open Access Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer Heather L Pulaski1 Gregory Spahlinger2 Ines A Silva2 Karen McLean1 Angela S Kueck1 R Kevin Reynolds1 George Coukos3 Jose R Conejo-Garcia4 and Ronald J Buckanovich 1 2 Address Department of Obstetrics and Gynecology University of Michigan Ann Arbor USA 2Department of Internal Medicine University of Michigan Ann Arbor USA 3Department of Obstetrics and Gynecology University of Pennsylvania Philadelphia USA and departments of Microbiology and Immunology Dartmouth Medical School Hanover USA Email Heather L Pulaski - heascott@ Gregory Spahlinger - Gspahlin@ Ines A Silva - iness@ Karen McLean - khajra@ Angela S Kueck - akueck@ R Kevin Reynolds - rkr@ George Coukos - gcks@ Jose R Conejo-Garcia - Ronald J Buckanovich - ronaldbu@ Corresponding author Published 19 June 2009 Received 7 January 2009 Journal of Translational Medicine 2009 7 49 doi l479-5876-7-49 Accepted 19 June 2009 This article is available from http content 7 1 49 2009 Pulaski et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Murine studies suggest that myeloid cells such as vascular leukocytes VLC and Tie2 monocytes play a critical role in tumor angiogenesis and vasculogenesis. Myeloid cells are a primary cause of resistance to anti-VEGF therapy. The elimination of these cells from the tumor microenvironment significantly restricts tumor growth in both spontaneous and xenograft murine tumor models. Thus animal studies indicate
